Kaleido Weighted Average Shares Diluted Trend from 2010 to 2021

KLDO -  USA Stock  

USD 5.69  0.03  0.52%

Kaleido Biosciences Weighted Average Shares Diluted yearly trend continues to be quite stable with very little volatility. The value of Weighted Average Shares Diluted is projected to decrease to about 27.6 M. From the period between 2010 and 2021, Kaleido Biosciences, Weighted Average Shares Diluted regression line of its data series had standard deviation of 11,153,711 and standard deviation of  11,153,711. Research and Development Expense is expected to rise to about 56 M this year, although the value of Consolidated Income will most likely fall to (88.1 M).

Search Historical Trends 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 2.2 M or Operating Expenses of 78.8 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.66 or Current Ratio of 4.08. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Biosciences Quarterly Weighted Average Shares Diluted

42.54 MillionShare

Kaleido Weighted Average Shares Diluted Breakdown

Showing smoothed Weighted Average Shares Diluted of Kaleido Biosciences with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPSDil]; determined based on the timing of issuance of shares or units in the period.Kaleido Biosciences' Weighted Average Shares Diluted historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kaleido Biosciences' overall financial position and show how it may be relating to other accounts over time.
Weighted Average Shares Diluted10 Years Trend
Increasing
Slightly volatile
 Weighted Average Shares Diluted 
Share
      Timeline 

Kaleido Weighted Average Shares Diluted Regression Statistics

Arithmetic Mean 10,630,988
Geometric Mean 7,195,849
Coefficient Of Variation 104.92
Mean Deviation 9,135,639
Median 4,469,614
Standard Deviation 11,153,711
Range 28,980,599
R-Value 0.75
R-Squared 0.57
Significance 0.004664
Slope 2,330,680

Kaleido Weighted Average Shares Diluted History

20185.1 M
201925.7 M
202033.5 M
202127.6 M

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's Weighted Average Shares Diluted, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Weighted Average Shares Diluted33.5 M27.6 M
Average Assets71.6 M82.7 M
Average Equity35.3 M38.1 M
Invested Capital Average20.9 M20 M
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
CEO Directory
Screen CEOs from public companies around the world
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.